Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Wang YM, Yi P. Global current research status and future hotspots in osteoporotic fracture based on bibliometric assessment and visualization techniques. World J Clin Cases 2024; 12(19): 3908-3917 [PMID: 38994286 DOI: 10.12998/wjcc.v12.i19.3908]
World J Clin Cases. Jul 6, 2024; 12(19): 3908-3917 Published online Jul 6, 2024. doi: 10.12998/wjcc.v12.i19.3908
Global current research status and future hotspots in osteoporotic fracture based on bibliometric assessment and visualization techniques
Yu-Ming Wang, Ping Yi
Yu-Ming Wang, Ping Yi, Department of Spine Surgery, China-Japan Friendship Hospital, Beijing 100029, China
Author contributions: Wang YM and Yi P have participated sufficiently in the work to take public responsibility for appropriate portions of the content and agreed to be accountable for all aspects of the work in ensuring that questions related to its accuracy or integrity.
Conflict-of-interest statement: The authors declare that there is no competing interest associated with the manuscript.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Corresponding author: Ping Yi, MD, Professor, China-Japan Friendship Hospital, Department of Spine Surgery, No. 2 East Yinghua Street, Chaoyang District, Beijing 100029, China. cjfh_ypspine@163.com
Received: March 10, 2024 Revised: April 26, 2024 Accepted: May 22, 2024 Published online: July 6, 2024 Processing time: 110 Days and 21.7 Hours
Core Tip
Core Tip: The evolution process of the research focus in the field of osteoporosis fractures in the past decade has changed from epidemiological statistics and long-term incidence prediction to osteoporosis fracture risk assessment and significant effects of zoledronic acid and denosumab on reducing fracture risk in osteoporosis treatment to the proposal of osteoporosis treatment guidelines and the adverse reactions caused by anti-osteoporosis drugs such as zoledronic acid. Current hot topics in the treatment of osteoporosis fractures include atypical femoral fractures, osteoporosis fractures caused by androgen deprivation, increased fracture risk due to denosumab discontinuation, hip fractures, trabecular bone scores, and genes related to bone density or osteoporosis fracture phenotypes.
